THE WHAT? Novo Nordisk is exploring hair loss as a potential new therapeutic category as the Ozempic and Wegovy manufacturer looks to expand its direct-to-consumer prescription drug business beyond diabetes and obesity.
THE DETAILS Novo Nordisk Chief Scientific Officer Martin Lange said hair loss is among several areas being considered alongside menopause and addiction, where the company sees potential overlap with its existing scientific expertise and growing direct-to-consumer capabilities. Some emerging hair-loss research is rooted in endocrinology and hormones, an area in which Novo Nordisk has extensive experience. Lange stressed that hair loss is not necessarily an immediate development priority, but described it as a potential opportunity for the company.
THE WHY? The exploration points to Novo Nordisk potentially moving into categories that increasingly intersect pharmaceuticals, personal care and consumer health, as the company looks for new growth opportunities and seeks to diversify beyond its blockbuster GLP-1 portfolio ahead of future patent expirations.
Source: Bloomberg
